HUB Organoids’ preclinical solutions for Immuno-oncology are built on our proprietary adult stem cell–derived organoid technology. By generating 3D tumor organoids from patient tissue and integrating immune components, we provide a human-relevant platform for evaluating immunotherapies with strong translational potential. Our co-culture systems, including both autologous and non-autologous formats, enable researchers to assess tumor-specific killing, immune cell activation, and cytokine release in a setting that mimics key elements of the tumor microenvironment. This approach supports the development of safer, more effective therapies tailored to patient-specific biology.
These challenges are amplified by the limitations of conventional preclinical models, which lack patient-specific tumor architecture and fail to simulate complex immune-tumor interactions. As a result, promising therapies often stumble in clinical phases, leading to costly attrition and missed therapeutic opportunities.
Non-autologous co-cultures pair healthy donor immune cells with tumor organoids from multiple patients. This approach enables the evaluation of immune-modulating agents across a broad range of tumor types and patient profiles.
How our client used basket trials in-a-dish for tumor indication selection
Autologous co-cultures combine patient-derived tumor organoids with matched immune cells—such as PBMCs or TILs—from the same individual. This format captures patient-specific immune recognition, antigen presentation, and tumor resistance mechanisms.
